News

Video

A Pooled Analysis of Trastuzumab Deruxtecan in Patients With HER2- Positive Metastatic Breast Cancer With Brain Metastases (BMs) from DESTINY-Breast01, -02, and -03

Author(s):

Sara M. Tolaney, MD, MPH

Sara Tolaney, MD, MPH, presents an exploratory pooled analysis of efficacy and safety data of trastuzumab deruxtecan vs comparator in patients with HER2-positive metastatic breast cancer and brain metastases from DESTINY-Breast01, -02, and -03.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Melanie A. Sheen, MD
the α-CORRECT study
Coy Heldermon, MD, PhD
AGAVE-201
Kevin Kalinsky, MD, MS, discusses the potential to switch CDK4/6 inhibitors in HR-positive metastatic breast cancer.
Dr Tolaney on Considerations for Adjuvant CDK4/6 Inhibitors in HR+/HER2-Negative Breast Cancer
Icro Meattini, ​MD, an associate professor in the Department of Clinical and Experimental Biomedical Sciences at the University of Florence; as well as a clinical oncologist in the Radiation Oncology Unit in the Oncology Department and head of the Breast Unit and Breast Cancer Multidisciplinary Team at Florence University Hospital
Related Content
Tanya Gupta, MD
March 19th 2025

Adjuvant CDK4/6 Inhibitors Lay a Solid Treatment Foundation in HR+, HER2– Breast Cancer

MedNews Week
January 1st 2025

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

2024 Tumor-Agnostic Approval Cheat Sheet: T-DXd and Repotrectinib
March 14th 2025

2024 Tumor-Agnostic Approval Cheat Sheet: T-DXd and Repotrectinib

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 10th 2025

Alisertib Plus Endocrine Therapy Is Under Evaluation in HR+/HER2-Negative Metastatic Breast Cancer

Hope S. Rugo, MD, professor of medicine and Winterhof Professor of Breast Oncology, director, Breast Oncology and Clinical Trials Education, University of California San Francisco Comprehensive Cancer Center
March 9th 2025

SERDs, PROTAC, and CERANs Offer Hope Following ET/CDK4/6 Inhibitor Resistance in Breast Cancer